<DOC>
	<DOCNO>NCT01146522</DOCNO>
	<brief_summary>This study ass safety , tolerability , effect LCQ908 blood lipid patient severe hypertriglyceridemia .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Assessment LCQ908 Patients With Severe Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Hyperlipoproteinemias</mesh_term>
	<criteria>Patients hyperlipoproteinemia Type I Type V willing medically able discontinue lipid lower medication ( prescribe ) . Non breast feed woman . Women child bear potential practicing appropriate contraception negative pregnancy test dosing . Patients : uncontrolled type 1 type 2 diabetes mellitus , active pancreatitis ( month prior study start ) , history drug alcohol abuse within 12 month prior dose , surgical medical condition , acute unstable chronic disease may , base investigator 's opinion , jeopardize patient case participation study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Familial hyperchylomicronemia</keyword>
	<keyword>Lipoprotein lipase deficiency</keyword>
	<keyword>Hyperlipoproteinemia</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>LCQ908</keyword>
	<keyword>Hyperlipoproteinemia associate lipoprotein lipase deficiency</keyword>
</DOC>